Current status of multiple markers in precision immunotherapy for colorectal cancer

References

1. 1.↵
   2. Duggan WP,
   3. Kisakol B,
   4. O’Connell E,
   5. Matveeva A,
   6. O’Grady T,
   7. McDonough E, et al.

   Multiplexed immunofluorescence imaging reveals an immune-rich tumor microenvironment in mucinous rectal cancer characterized by increased lymphocyte infiltration and enhanced programmed cell death protein 1 expression. Dis Colon Rectum. 2022; 66: 914–22.

   OpenUrlPubMed
2. 2.↵
   2. Alvi MA,
   3. Loughrey MB,
   4. Dunne P,
   5. McQuaid S,
   6. Turkington R,
   7. Fuchs M-A, et al.

   Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer. 2017; 117: 203–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Parente P,
   3. Mastracci L,
   4. Vanoli A,
   5. Businello G,
   6. Paudice M,
   7. Angerilli V, et al.

   Colorectal adenosquamous carcinoma: peculiar morphologic features and distinct immunoprofiles in squamous and glandular components. Pathol Res Pract. 2022; 236: 153967.
4. 4.↵
   2. Yılmaz O,
   3. Crabbe A,
   4. Neyaz A,
   5. Pankaj A,
   6. Lee SH,
   7. Hosseini S, et al.

   Clinical, pathological genetics and intratumoral immune milieu of serrated adenocarcinoma of the colon. Histopathology. 2022; 81: 380–8.

   OpenUrlPubMed
5. 5.↵
   2. Liu C,
   3. Zou H,
   4. Ruan Y,
   5. Fang L,
   6. Wang B,
   7. Cui L, et al.

   Multiomics reveals the immunologic features and the immune checkpoint blockade potential of colorectal medullary carcinoma. Clin Cancer Res. 2025; 31: 773–86.

   OpenUrlPubMed
6. 6.↵
   2. Loupakis F,
   3. Depetris I,
   4. Biason P,
   5. Intini R,
   6. Prete AA,
   7. Leone F, et al.

   Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes. Oncologist. 2020; 25: 481–7.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Loree JM,
   3. Titmuss E,
   4. Topham JT,
   5. Kennecke HF,
   6. Feilotter H,
   7. Virk S, et al.

   Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 Trial. Clin Cancer Res. 2024; 30: 3189–99.

   OpenUrlPubMed
8. 8.↵
   2. Bortolomeazzi M,
   3. Keddar MR,
   4. Montorsi L,
   5. Acha-Sagredo A,
   6. Benedetti L,
   7. Temelkovski D, et al.

   Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology. 2021; 161: 1179–93.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. Ganesh K,
   3. Stadler ZK,
   4. Cercek A,
   5. Mendelsohn RB,
   6. Shia J,
   7. Segal NH, et al.

   Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16: 361–75.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Mehrvarz Sarshekeh A,
    3. Alshenaifi J,
    4. Roszik J,
    5. Manyam GC,
    6. Advani SM,
    7. Katkhuda R, et al.

    ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable colorectal cancer. Clin Cancer Res. 2021; 27: 1663–70.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    2. Liu R,
    3. Niu Y,
    4. Liu C,
    5. Zhang X,
    6. Zhang J,
    7. Shi M, et al.

    Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. Cancer Sci. 2023; 114: 1229–39.

    OpenUrlPubMed
12. 12.↵
    2. Pagès F,
    3. Mlecnik B,
    4. Marliot F,
    5. Bindea G,
    6. Ou F-S,
    7. Bifulco C, et al.

    International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391: 2128–39.

    OpenUrlCrossRefPubMed
13. 13.↵
    2. Zhang C,
    3. Li D,
    4. Xiao B,
    5. Zhou C,
    6. Jiang W,
    7. Tang J, et al.

    B2M and JAK1/2-mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy. J Immunother. 2022; 45: 187–93.

    OpenUrlCrossRef
14. 14.↵
    2. Torrejon DY,
    3. Galvez M,
    4. Abril-Rodriguez G,
    5. Campbell KM,
    6. Medina E,
    7. Vega-Crespo A, et al.

    Antitumor immune responses in B2M-deficient cancers. Cancer Immunol Res. 2023; 11: 1642–55.

    OpenUrlPubMed
15. 15.↵
    2. Zou Q,
    3. Wang X,
    4. Ren D,
    5. Hu B,
    6. Tang G,
    7. Zhang Y, et al.

    DNA methylation-based signature of CD8⁺ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021; 9: e002671.
16. 16.↵
    2. Prat A,
    3. Navarro A,
    4. Paré L,
    5. Reguart N,
    6. Galván P,
    7. Pascual T, et al.

    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. Cancer Res. 2017; 77: 3540–50.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    2. Cristescu R,
    3. Mogg R,
    4. Ayers M,
    5. Albright A,
    6. Murphy E,
    7. Yearley J, et al.

    Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362: eaar3593.
18. 18.↵
    2. Manohar SM.

    At the crossroads of TNF α signaling and cancer. Curr Mol Pharmacol. 2024; 17: e060923220758.
19. 19.↵
    2. Glaviano A,
    3. Lau HS,
    4. Carter LM,
    5. Lee EHC,
    6. Lam HY,
    7. Okina E, et al.

    Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025; 18: 6.

    OpenUrlPubMed
20. 20.↵
    2. Lin A,
    3. Jiang A,
    4. Huang L,
    5. Li Y,
    6. Zhang C,
    7. Zhu L, et al.

    From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy. Gut Microbes. 2025; 17: 2452277.